Adrenergic receptor activation triggers stress-induced dystonia in a CACNA1A mutant mouse model

Pauline Bohne1, Michelle Grömmke2, Max Rybarski1

  • 1Department of Behavioral Neuroscience, Ruhr-University Bochum, Bochum, Germany.

Insights

Adrenergic receptor (AR) signaling in cerebellar Purkinje cells influences stress-induced dystonia in Episodic Ataxia type 2 (EA2). Blocking alpha-2 ARs completely abolished dystonia, suggesting ARs as therapeutic targets.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Episodic ataxia type 2 (EA2) stems from CACNA1A mutations, impairing P/Q-type Ca2+ channels in cerebellar Purkinje cells (PCs), leading to ataxia and dystonia.
  • Stress-induced dystonia is a key symptom in EA2, but its underlying mechanisms involving cerebellar circuitry remain unclear.

Purpose of the Study:

  • To investigate the role of adrenergic receptors (ARs) in modulating stress-induced dystonia in a mouse model of EA2.
  • To explore potential therapeutic targets within the cerebellar adrenergic system for EA2.

Main Methods:

  • Utilized Cacna1a purk(-/-) (purky) mice with selective P/Q-type Ca2+ channel deletion in PCs.
  • Administered various adrenergic receptor antagonists (prazosin, BMY-7378, yohimbine) and an alpha2A-AR agonist.
  • Performed electrophysiological recordings of cerebellar PCs and histological analyses (DβH, LC neuron counts).

Main Results:

  • Alpha1-AR blockade had mixed effects, while alpha1D-AR blockade reduced dystonia frequency.
  • Universal blockade of alpha2-ARs with yohimbine, or alpha2A-AR agonism, completely abolished stress-induced dystonia.
  • Norepinephrine inhibited PC firing, partially rescued by yohimbine, indicating alpha2-AR modulation.
  • Increased cerebellar noradrenergic innervation was observed in purky mice.

Conclusions:

  • Enhanced noradrenergic innervation to cerebellar PCs facilitates stress-induced dystonia in EA2.
  • Alpha2-AR signaling plays a critical role in the pathophysiology of dystonia in EA2.
  • Cerebellar adrenergic receptors represent promising therapeutic targets for EA2 management.